Strategic Analysis on World Congestive Heart Failure (CHF) Treatment Devices Market 2022 - PowerPoint PPT Presentation

Loading...

PPT – Strategic Analysis on World Congestive Heart Failure (CHF) Treatment Devices Market 2022 PowerPoint presentation | free to download - id: 840c92-OGVkN



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Strategic Analysis on World Congestive Heart Failure (CHF) Treatment Devices Market 2022

Description:

Get a sample brochure @ Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs). – PowerPoint PPT presentation

Number of Views:26

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Strategic Analysis on World Congestive Heart Failure (CHF) Treatment Devices Market 2022


1
World Congestive Heart Failure (CHF) Treatment
Devices Market - Opportunities and Forecasts,
2015 - 2022
Published Date 01 May, 2016 No of Pages
135 Single User Price 4740
World CHF Treatment Devices Market is estimated
to reach 14,823.3 million by 2022
Click Here To Check Complete Report
2
  • Congestive heart failure (CHF) is a physiological
    condition that has an adverse impact on the
    pumping efficiency of the cardiac muscles.
  • It characterizes the accumulation of fluid around
    the heart leading to inefficient pumping.
  • The onset of CHF is marked by the failure of the
    ventricles to pump sufficient volume of blood to
    the body organs.
  • This eventually leads to deposition of fluid in
    the lungs, abdomen, liver, and lower body.
  • CHF is treated by a number of devices that
    maintain heart rhythm, such as pacemakers,
    cardiac resynchronization therapy (CRT),
    implantable cardioverter defibrillators (ICDs),
    and ventricular assist devices (VADs).
  • The world CHF treatment devices market was
    evaluated at 10,127.2 million in 2015, and is
    estimated to reach 14,823.3 million by 2022,
    with a CAGR of 5.5 over the forecast period.
  • This is primarily attributed to the constantly
    changing lifestyle habits (such as unhealthy
    dietary habits, excessive alcohol consumption,
    smoking, obesity, and lack of physical activity)
    which make individuals more susceptible to
    arrhythmia and heart failure.

3
  • In addition, a number of factors such as the
    large number of technological advancements in CHF
    treatment devices, increased adoption rate of
    these devices, and rising emphasis on early
    intervention and primary prevention of
    heart-related disorders are responsible for
    driving the market.
  • Conversely, stringent government regulations for
    the approval of CHF treatment devices, high cost
    of, and high preference to drugs for CHF
    treatment are some of the factors restraining the
    market growth.
  • The report segments the world CHF treatment
    devices market based on product type, namely,
    pacemakers, cardiac resynchronization therapy
    (CRT) devices, implantable cardioverter
    defibrillators (ICDs), and ventricular assist
    devices (VADs).
  • Pacemaker is further segmented into dual-chamber
    pacemakers and single-chamber pacemakers.
  • CRT devices is segmented into two major types,
    namely, CRT-P and CRT-D. ICDs is further
    segmented into transvenous implantable
    cardioverter defibrillator (T-ICDs) and
    subcutaneous implantable cardioverter
    defibrillator (S-ICDs).
  • VADs is also segmented into left ventricular
    assist device (LVAD), right ventricular assist
    device (RVAD), and biventricular assist device
    (BIVAD).

4
  • ICDs was the highest revenue-generating segment
    in 2015, owing to the stressful hyperactive
    lifestyle, unhealthy food habits, and growing
    number of aging population.
  • Based on geography, the market is divided into
    North America, Europe, Asia-Pacific, and LAMEA
    regions.
  • The key players in this market adopted product
    development and product launch as their key
    strategies to keep pace with the changing demands
    of consumers.
  • Furthermore, companies launched cost-effective
    and technologically efficient products to
    strengthen their market position.
  • The report provides a comprehensive analysis of
    the key players operating in the world CHF
    treatment devices market, such as Abiomed, Inc.,
    Berlin Heart GmbH, Biotronik SE Co. KG, Boston
    Scientific Corporation, HeartWare International,
    Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic
    plc, ReliantHeart Inc., and St. Jude Medical,
    Inc.
  • Key Benefits The study provides an in-depth
    analysis of the world CHF treatment devices
    market with current trends and future estimations
    to elucidate the imminent investment pockets in
    the market.

Make an Inquiry Before Buying
5
  • The report provides a comprehensive analysis of
    the key players operating in the world CHF
    treatment devices market, such as Abiomed, Inc.,
    Berlin Heart GmbH, Biotronik SE Co. KG, Boston
    Scientific Corporation, HeartWare International,
    Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic
    plc, ReliantHeart Inc., and St. Jude Medical,
    Inc.
  • Key Benefits The study provides an in-depth
    analysis of the world CHF treatment devices
    market with current trends and future estimations
    to elucidate the imminent investment pockets in
    the market.
  • The report provides a quantitative analysis from
    2015 to 2022 that would enable the stakeholders
    to capitalize on prevailing market opportunities.
  • Extensive analysis of the world CHF treatment
    devices market, by product, helps in
    understanding the various types of devices used
    for the treatment of CHF and other related
    cardiac conditions.
  • Competitive intelligence highlights the business
    practices followed by leading market players
    across various geographic regions.

Download Sample Brochure
6
  • SWOT analysis enables to study the internal
    environment of the leading companies for strategy
    formulation.
  • CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES
    MARKET KEY SEGMENTS Congestive Heart Failure
    (CHF) Treatment Devices Market,
  • By Product Pacemakers,
  • By Type Implantable Pacemakers External
    Pacemakers Cardiac Resynchronization Therapy
    (CRT), By Type Cardiac Resynchronization
    Therapy-Pacemakers (CRT-P)Cardiac
    Resynchronization Therapy-Defibrillators
    (CRT-D)Implantable Cardioverter Defibrillators
    (ICDs),
  • By TypeTransvenous Implantable Cardioverter
    Defibrillator (T-ICDs)Subcutaneous Implantable
    Cardioverter Defibrillator (S-ICDs)Ventricular
    Assist Devices (VADs),
  • By Type Left Ventricular Assist Device
    (LVAD)Right Ventricular Assist Device
    (RVAD)Biventricular Assist Device (BIVAD)
  • By Geography North AmericaU.S.CanadaMexicoEuropeGe
    rmanyU.K.FranceRest of EuropeAsia-PacificJapanChin
    aIndiaRest of Asia-PacificLAMEALatin
    AmericaMiddle EastAfrica

7
World Congestive Heart Failure (CHF) Treatment
Devices Market - Opportunities and Forecasts,
2015 - 2022
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the World Congestive Heart Failure (CHF)
Treatment Devices Market and future opportunities
are provided in the report.
Contact 1-302-261-5343 sales_at_marketintelreports.
com www.marketintelreports.com
Click here to order a copy of World Congestive
Heart Failure (CHF) Treatment Devices Market
Report
About PowerShow.com